Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTX NASDAQ:NKTR NASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsNKTRNektar Therapeutics$71.04$69.60$21.02▼$109.00$2.40B1.131.23 million shs1.12 million shsWGSGeneDx$67.51$54.42$32.21▼$170.87$2.00B1.91.07 million shs925,851 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+362.46%NKTRNektar Therapeutics+10.33%+14.53%+21.31%-7.73%+178.26%WGSGeneDx-5.86%-1.69%+27.07%+1.98%-24.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$221.38+0.0%$220.96$18.51▼$221.42$6.96B1.52928,762 shs2.69 million shsNKTRNektar Therapeutics$71.04$69.60$21.02▼$109.00$2.40B1.131.23 million shs1.12 million shsWGSGeneDx$67.51$54.42$32.21▼$170.87$2.00B1.91.07 million shs925,851 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics0.00%0.00%0.00%0.00%+362.46%NKTRNektar Therapeutics+10.33%+14.53%+21.31%-7.73%+178.26%WGSGeneDx-5.86%-1.69%+27.07%+1.98%-24.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 2.30Hold$169.88-23.27% DownsideNKTRNektar Therapeutics 2.73Moderate Buy$149.63110.62% UpsideWGSGeneDx 2.50Moderate Buy$87.4329.50% UpsideCurrent Analyst Ratings BreakdownLatest NKTR, CDTX, and WGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026WGSGeneDx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.00 ➝ $74.006/29/2026WGSGeneDx Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/23/2026WGSGeneDx Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$50.00 ➝ $63.006/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026WGSGeneDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026WGSGeneDx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026NKTRNektar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$95.00 ➝ $80.005/8/2026NKTRNektar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$105.00 ➝ $192.005/5/2026WGSGeneDx Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.005/5/2026WGSGeneDx Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$100.00 ➝ $75.005/5/2026WGSGeneDx Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$155.00 ➝ $75.00(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara TherapeuticsN/AN/AN/AN/A$14.92 per shareN/ANKTRNektar Therapeutics$55.63M43.14N/AN/A$4.41 per share16.11WGSGeneDx$442.68M4.53$2.16 per share31.29$10.54 per share6.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$169.83M-$11.78N/AN/AN/AN/A-45.52%-38.31%N/ANKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)WGSGeneDx-$21.02M-$2.68N/A77.60N/A-17.58%9.15%5.21%8/4/2026 (Estimated)Latest NKTR, CDTX, and WGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 million5/4/2026Q1 2026WGSGeneDx-$0.06-$0.28-$0.22-$2.16$112.46 million$102.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A4.624.62NKTRNektar TherapeuticsN/A10.2110.21WGSGeneDx0.383.092.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%NKTRNektar Therapeutics75.88%WGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics3.89%NKTRNektar Therapeutics2.50%WGSGeneDx25.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9031.44 million30.22 millionNo DataNKTRNektar Therapeutics22033.79 million32.94 millionOptionableWGSGeneDx1,30029.69 million22.22 millionOptionableNKTR, CDTX, and WGS HeadlinesRecent News About These CompaniesHBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge1 hour ago | globenewswire.comGeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP2 hours ago | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm4 hours ago | newsfilecorp.comNGeneDx Holdings Corp. (NASDAQ:WGS) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 3 at 2:15 AM | americanbankingnews.comGeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 3 at 2:13 AM | marketbeat.comINVESTOR ALERT: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 2 at 6:30 PM | newsfilecorp.comNROSEN, A TOP-RANKED LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGSJuly 2 at 5:51 PM | globenewswire.comWGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud LawsuitJuly 2 at 5:50 PM | prnewswire.comGeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCJuly 2 at 5:37 PM | newsfilecorp.comNWGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law FirmJuly 2 at 11:14 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines - WGSJuly 2 at 10:00 AM | prnewswire.comHBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment ChargeJuly 2 at 9:00 AM | prnewswire.comPeregrine Capital Management LLC Has $4.60 Million Stock Position in GeneDx Holdings Corp. $WGSJuly 2 at 5:19 AM | marketbeat.comGeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCJuly 1 at 5:36 PM | newsfilecorp.comNGeneDx Holdings Corp. (WGS) Class Action Lawsuit Seeks Recovery for Investors; August 3, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLPJuly 1 at 5:25 PM | prnewswire.comWGS Stockholders Have Rights – If You Lost Money Investing in GeneDx Holdings Corp. Contact Robbins LLP for Information About Recovering Your LossesJuly 1 at 5:06 PM | globenewswire.comROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGSJuly 1 at 3:23 PM | newsfilecorp.comNBronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor HarmJuly 1 at 12:00 PM | globenewswire.comWGS DEADLINE: Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of Upcoming Securities Class Action DeadlineJuly 1 at 10:09 AM | prnewswire.comGENEDX HOLDINGS CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 3, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces DeadlineJuly 1 at 9:34 AM | globenewswire.comGeneDx (NASDAQ:WGS) Downgraded by Zacks Research to "Strong Sell"July 1 at 7:05 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKTR, CDTX, and WGS Company DescriptionsCidara Therapeutics NASDAQ:CDTXCidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Nektar Therapeutics NASDAQ:NKTR$71.04 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$71.11 +0.07 (+0.10%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.GeneDx NASDAQ:WGS$67.51 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$67.72 +0.21 (+0.31%) As of 07/2/2026 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
